CytoSorbents Appeals to FDA for De Novo Review of DrugSorb™-ATR Approval CytoSorbents Corporation has filed an appeal with the FDA regarding the denial of its DrugSorb-ATR device. The device aims to manage bleeding in cardiac surgeries.

CytoSorbents Appeals to FDA for De Novo Review of DrugSorb™-ATR Approval #United_States #Princeton #CytoSorbents #DrugSorb-ATR #FDA_Appeal